Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$45.43-7.36%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TRAX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain a two-year cash runway and control operating losses during clinical development | First Tracks is advancing its drug ANB033 through early clinical trials with a two-year cash runway. | Intact | Cash runway falls below 12 months before new funding or revenue | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
TRAX is a clinical-stage biotechnology company, so its long-term thesis depends on advancing treatments rather than established product performance. The thesis is marked intact this week, but confidence is low and management execution is mixed.
The evidence snapshot provides no valuation level or expectations estimate, so it is not possible to say whether TRAX looks cheap, fair, or expensive versus peers. No fragility gates fired, which suggests limited signs of fragile expectations in the supplied assessment, but it does not establish what the market already assumes.
Near term, the risk of an earnings miss is elevated, and a guidance cut would be a meaningful negative. Management reports progress on ANB033 and cash runway into Q2 2028, but clinical outcomes are not provided and the company continues to report operating losses. Recent risk moved from elevated to moderate, while overall financial performance remains neutral.
Over the next few quarters, the thesis depends on whether management delivers clinical milestones and maintains enough cash to fund development. A guidance cut or further weakness in jobs data could add pressure, while continued strong results and guidance from healthcare sector bellwethers could support the sector backdrop. The recent private placements and capital-allocation event add context, but the supplied evidence does not describe their terms or effects.
For the next 1 to 3 years, TRAX remains a high-uncertainty clinical development story with a stated cash runway and an intact thesis, but little evidence yet that key clinical or strategic milestones have been delivered. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The firm is investing heavily now to reach Phase 2 trials in multiple indications. |
| Intact |
| Failure to initiate Phase 2 trials in at least two indications by 2028 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: ““ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort.” “These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet,” said Daniel Faga, president and chief executive officer.” Delivery assessment Nov 5, 2026 |
Complete separation from AnaptysBio and establish independent operations | The company completed its spin-off and is building operational independence. | Intact | Failure to maintain independent operations or loss of key agreements by 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.99 → $-3.56 · observed estimates
FY2027 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-08-13 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-14 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-15 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-16 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-17 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-18 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-19 | $-2.99 | Unavailable | 6 / 0 |
| 2026-08-20 | $-3.23 | Unavailable | 6 / 0 |
| 2026-08-21 | $-3.23 | Unavailable | 6 / 0 |
| 2026-08-22 | $-3.23 | Unavailable | 6 / 0 |
| 2026-08-23 | $-3.84 | Unavailable | 6 / 0 |
| 2026-08-24 | $-3.84 | Unavailable | 6 / 0 |
| 2026-08-25 | $-3.66 | Unavailable | 6 / 0 |
| 2026-08-26 | $-3.66 | Unavailable | 6 / 0 |
| 2026-08-27 | $-3.66 | Unavailable | 6 / 0 |
| 2026-08-28 | $-3.66 | Unavailable | 6 / 0 |
| 2026-08-29 | $-3.66 | Unavailable | 6 / 0 |
| 2026-08-30 | $-3.66 | Unavailable | 6 / 0 |
| 2026-08-31 | $-3.66 | Unavailable | 6 / 0 |
| 2026-09-01 | $-3.66 | Unavailable | 6 / 0 |
| 2026-09-02 | $-3.66 | Unavailable | 6 / 0 |
| 2026-09-03 | $-3.66 | Unavailable | 6 / 0 |
| 2026-09-04 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-05 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-06 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-07 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-08 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-09 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-10 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-11 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-12 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-13 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-14 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-15 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-16 | $-3.75 | Unavailable | 6 / 0 |
| 2026-09-17 | $-3.78 | Unavailable | 6 / 0 |
| 2026-09-18 | $-3.78 | Unavailable | 6 / 0 |
| 2026-09-19 | $-3.78 | Unavailable | 6 / 0 |
| 2026-09-20 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-21 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-22 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-23 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-24 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-25 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-26 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-27 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-28 | $-3.78 | Unavailable | 7 / 0 |
| 2026-09-29 | $-3.72 | Unavailable | 7 / 0 |
| 2026-09-30 | $-3.72 | Unavailable | 7 / 0 |
| 2026-10-01 | $-3.72 | Unavailable | 7 / 0 |
| 2026-10-02 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-03 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-04 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-05 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-06 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-07 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-08 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-09 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-10 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-11 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-12 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-13 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-14 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-15 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-16 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-17 | $-3.64 | Unavailable | 7 / 0 |
| 2026-10-18 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-19 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-20 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-21 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-22 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-23 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-24 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-25 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-26 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-27 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-28 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-29 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-30 | $-3.68 | Unavailable | 7 / 0 |
| 2026-10-31 | $-3.68 | Unavailable | 7 / 0 |
| 2026-11-01 | $-3.68 | Unavailable | 7 / 0 |
| 2026-11-02 | $-3.68 | Unavailable | 7 / 0 |
| 2026-11-03 | $-3.68 | Unavailable | 7 / 0 |
| 2026-11-04 | $-3.56 | Unavailable | 7 / 0 |
| 2026-11-05 | $-3.56 | Unavailable | 7 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 5 recorded
4 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.